Norma Jung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Norma Jung has a total of 297 co-authors. Here are the top co-authors by number of shared publications:
- Ayla Yagdiran
Department of Orthopedic and Trauma Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
11 shared publications - Peer Eysel
Department of Orthopedics and Trauma Surgery, Faculty of Medicine, University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
9 shared publications - Charlotte Meyer-Schwickerath
Division of Infectious Diseases, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne , Cologne
8 shared publications - Clara Lehmann
University of Cologne
7 shared publications Gerd Fätkenheuer
Department I of Internal Medicine, University Hospital Cologne, Faculty of Medicine, University of Cologne, German Center for Infection Research Partner Side Köln‐Bonn University of Cologne Cologne Germany
6 shared publications- Katrin Mehler
Department of Neonatology University Hospital of Cologne Cologne Germany
6 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Springer Nature in Infection
- Vol. 54 (4) , 1931-1943
Impact of an antimicrobial stewardship intervention on carbapenem use in children with cancer
Purpose: Infections during neutropenia are a potentially life-threatening complication in pediatric oncology. International guidelines recommend antipseudomonal β-lactam monotherapy for stable patients, however, modification to carbapenems often occurs without confirmed infection. Methods: We conducted a retrospective cohort study at a single tertiary pediatric oncology center to assess the impact of a carbapenem-sparing AMS intervention in children during neutropenia. All pediatric cancer patients with at least one episode of suspected infection between January 2021 and October 2024 were included. The intervention combined training, updated standard operating procedures, multidrug-resistant (MDR) surveillance swabs, and a structured protocol reassessing meropenem treatment. Results: Among 254 patients, 116 met the inclusion criteria, accounting for 432 episodes (270 pre- and 162 post-intervention). Re-modification of antimicrobial therapy from meropenem to piperacillin/tazobactam was achieved in 16 of 50 post-intervention episodes. The median duration of meropenem treatment decreased from 9 to 6 days ( p = 0.006 ). Interrupted time series analysis showed a non-significant reduction in meropenem use, corresponding to an estimated decline of 40.7 days of therapy (DOT) per 1000 patient-days per quarter. Mortality was unchanged (3.8% vs 4.3%). Conclusion: Our findings demonstrate that a structured AMS intervention is feasible and effective in pediatric oncology, reducing unnecessary meropenem exposure without compromising safety. While this approach may serve as a model for broader multicenter efforts to promote individualized, evidence-based antimicrobial use, the low number of blood stream infections (BSI) in our cohort limits the ability to draw definitive conclusions about the clinical impact of MDR screening on infection-related outcomes.
- 1 June 2026
- Published by Springer Nature in Infection
- Vol. 54 (4) , 1931-1943
Open AccessImpact of an antimicrobial stewardship intervention on carbapenem use in children with cancer
Purpose: Infections during neutropenia are a potentially life-threatening complication in pediatric oncology. International guidelines recommend antipseudomonal β-lactam monotherapy for stable patients, however, modification to carbapenems often occurs without confirmed infection. Methods: We conducted a retrospective cohort study at a single tertiary pediatric oncology center to assess the impact of a carbapenem-sparing AMS intervention in children during neutropenia. All pediatric cancer patients with at least one episode of suspected infection between January 2021 and October 2024 were included. The intervention combined training, updated standard operating procedures, multidrug-resistant (MDR) surveillance swabs, and a structured protocol reassessing meropenem treatment. Results: Among 254 patients, 116 met the inclusion criteria, accounting for 432 episodes (270 pre- and 162 post-intervention). Re-modification of antimicrobial therapy from meropenem to piperacillin/tazobactam was achieved in 16 of 50 post-intervention episodes. The median duration of meropenem treatment decreased from 9 to 6 days ( p = 0.006 ). Interrupted time series analysis showed a non-significant reduction in meropenem use, corresponding to an estimated decline of 40.7 days of therapy (DOT) per 1000 patient-days per quarter. Mortality was unchanged (3.8% vs 4.3%). Conclusion: Our findings demonstrate that a structured AMS intervention is feasible and effective in pediatric oncology, reducing unnecessary meropenem exposure without compromising safety. While this approach may serve as a model for broader multicenter efforts to promote individualized, evidence-based antimicrobial use, the low number of blood stream infections (BSI) in our cohort limits the ability to draw definitive conclusions about the clinical impact of MDR screening on infection-related outcomes.
- Open Access
- 25 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Health-Related Quality of Life of Patients With Infective Endocarditis—A Cross-Sectional Study Based on Data From the DERIVE Cohort
Background: Infective endocarditis (IE) remains a severe condition with high morbidity and mortality despite advances in diagnostics and therapy. Health-related quality of life (HRQL) is an important outcome, yet high-quality data on HRQL in patients with IE are limited as most studies focused exclusively on surgically treated patients and did not assess HRQL at a defined time point. Methods: A cross-sectional analysis was performed on HRQL data from 259 patients diagnosed with IE between 11/2019 and 09/2023, derived from the prospective German DERIVE cohort. HRQL was evaluated 12 months after diagnosis using the EQ-5D-5L questionnaire and the EQ visual analog scale (EQ-VAS). Descriptive and nonparametric analyses were applied to compare HRQL across subgroups. Results: Of 338 one-year survivors, complete HRQL data were available for 259 patients (77%). The median EQ-5D index (interquartile range) was 0.91 (0.73–0.97), indicating persistent impairment compared with the general population. Female patients had lower HRQL than males (median EQ-5D index, 0.89 vs 0.91) and higher impairments in anxiety, pain, and usual activities. Younger patients (<55 years) experienced higher overall HRQL but more pain and anxiety, while patients older than 65 years reported greater physical limitations. No significant difference in EQ-5D index was observed between surgically and conservatively treated patients (0.91 vs 0.90); however, surgically treated patients reported higher levels of anxiety 1 year after diagnosis. Conclusions: Patients with IE experience persistent reductions in HRQL 1 year after diagnosis, affecting nearly all domains of daily life. The data highlight the importance of incorporating patient-reported outcomes into clinical management and long-term follow-up.
- 25 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Open AccessHealth-Related Quality of Life of Patients With Infective Endocarditis—A Cross-Sectional Study Based on Data From the DERIVE Cohort
Background: Infective endocarditis (IE) remains a severe condition with high morbidity and mortality despite advances in diagnostics and therapy. Health-related quality of life (HRQL) is an important outcome, yet high-quality data on HRQL in patients with IE are limited as most studies focused exclusively on surgically treated patients and did not assess HRQL at a defined time point. Methods: A cross-sectional analysis was performed on HRQL data from 259 patients diagnosed with IE between 11/2019 and 09/2023, derived from the prospective German DERIVE cohort. HRQL was evaluated 12 months after diagnosis using the EQ-5D-5L questionnaire and the EQ visual analog scale (EQ-VAS). Descriptive and nonparametric analyses were applied to compare HRQL across subgroups. Results: Of 338 one-year survivors, complete HRQL data were available for 259 patients (77%). The median EQ-5D index (interquartile range) was 0.91 (0.73–0.97), indicating persistent impairment compared with the general population. Female patients had lower HRQL than males (median EQ-5D index, 0.89 vs 0.91) and higher impairments in anxiety, pain, and usual activities. Younger patients (<55 years) experienced higher overall HRQL but more pain and anxiety, while patients older than 65 years reported greater physical limitations. No significant difference in EQ-5D index was observed between surgically and conservatively treated patients (0.91 vs 0.90); however, surgically treated patients reported higher levels of anxiety 1 year after diagnosis. Conclusions: Patients with IE experience persistent reductions in HRQL 1 year after diagnosis, affecting nearly all domains of daily life. The data highlight the importance of incorporating patient-reported outcomes into clinical management and long-term follow-up.
- Open Access
- 23 May 2025
- Published by MDPI AG in Diabetology
- Vol. 6 (6) , 45
Age-Dependent Loss of Sirtuin1 (Sirt1) Correlates with Reduced Autophagy in Type 2 Diabetic Patients (T2DM)
Aims and Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder frequently associated with increased inflammation and dysregulated innate immune responses. Thus, patients with T2DM are predisposed to bacterial infections. However, the underlying mechanism is poorly understood. The NAD+-dependent deacetylase Sirtuin1 (SIRT1) plays an important role in regulating cellular metabolism, including T2DM and aging. Furthermore, we have recently demonstrated that SIRT1 critically regulates inflammatory pathways and autophagy during infection. Thus, we aimed to investigate SIRT1 expression and its correlation with autophagy in peripheral blood mononuclear cells (PBMCs) from patients with T2DM compared to non-diabetic patients. Methods: Clinical characteristics of the study subjects were obtained. SIRT1 and autophagic markers such as p62 and LC3-I/II were determined using Western blot analysis followed by densitometric analysis. Results: We found that SIRT1 levels were decreased in PBMCs of diabetic patients in an age-dependent manner. Importantly, reduced SIRT1 expression correlated with reduced LC3-II/I ratios, indicating reduced autophagy. Reduced SIRT1 also corresponded to decreased autophagic adaptor protein Sequestome-1/p62. Conclusions: In summary, our results suggest a potential role of SIRT1 in regulating autophagy in PBMCs from T2DM patients.
- 23 May 2025
- Published by MDPI AG in Diabetology
- Vol. 6 (6) , 45
Open AccessAge-Dependent Loss of Sirtuin1 (Sirt1) Correlates with Reduced Autophagy in Type 2 Diabetic Patients (T2DM)
Aims and Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder frequently associated with increased inflammation and dysregulated innate immune responses. Thus, patients with T2DM are predisposed to bacterial infections. However, the underlying mechanism is poorly understood. The NAD+-dependent deacetylase Sirtuin1 (SIRT1) plays an important role in regulating cellular metabolism, including T2DM and aging. Furthermore, we have recently demonstrated that SIRT1 critically regulates inflammatory pathways and autophagy during infection. Thus, we aimed to investigate SIRT1 expression and its correlation with autophagy in peripheral blood mononuclear cells (PBMCs) from patients with T2DM compared to non-diabetic patients. Methods: Clinical characteristics of the study subjects were obtained. SIRT1 and autophagic markers such as p62 and LC3-I/II were determined using Western blot analysis followed by densitometric analysis. Results: We found that SIRT1 levels were decreased in PBMCs of diabetic patients in an age-dependent manner. Importantly, reduced SIRT1 expression correlated with reduced LC3-II/I ratios, indicating reduced autophagy. Reduced SIRT1 also corresponded to decreased autophagic adaptor protein Sequestome-1/p62. Conclusions: In summary, our results suggest a potential role of SIRT1 in regulating autophagy in PBMCs from T2DM patients.
- Open Access
- 3 March 2025
- Published by Springer Nature in Infection
- Vol. 53 (4) , 1535-1540
UniteID– a proposal for training pediatric ID specialists supported by an adult ID program
- 3 March 2025
- Published by Springer Nature in Infection
- Vol. 53 (4) , 1535-1540
Open AccessUniteID– a proposal for training pediatric ID specialists supported by an adult ID program
- Open Access
- 7 November 2024
- Published by Springer Nature in Die Innere Medizin
- Vol. 65 (11) , 1053-1055
Neues zu Impfungen
- 7 November 2024
- Published by Springer Nature in Die Innere Medizin
- Vol. 65 (11) , 1053-1055
Open AccessNeues zu Impfungen
- Open Access
- 1 October 2024
- Published by Springer Nature in rheuma plus
- Vol. 24 (3) , 167-170
Knochen‑, Gelenk- und periprothetische Infektionen – eine interdisziplinäre Herausforderung
Zusammenfassung: Knochen- und Gelenkinfektionen umfassen ein breites Spektrum an Entitäten, insbesondere die Inzidenz von periprothetischen Infektionen, diabetischen Fußinfektionen und Spondylodiszitiden ist weiter zunehmend. Das Management ist komplex und ein interdisziplinäres Team aus v. a. Chirurgen, Infektiologen und Mikrobiologen ist zur Therapieplanung dringend zu involvieren. Die Evidenz zu den Behandlungsmöglichkeiten ist eher niedrig, aber in den letzten Jahren wurden einige Landmarkstudien veröffentlicht. Für die native Spondylodiszitis konnte eine Nichtunterlegenheit für eine 6‑ vs. 12-wöchige Antibiotikatherapie gezeigt werden, bei den periprothetischen Infektionen konnte die Nichtunterlegenheit für die 6‑wöchige Therapie dagegen nicht bestätigt werden. Eine frühe Oralisierung (innerhalb von 7 Tagen) bei verschiedenen Knocheninfektionen war nicht unterlegen, eine intravenöse Mindesttherapiedauer wird nicht mehr empfohlen.
- 1 October 2024
- Published by Springer Nature in rheuma plus
- Vol. 24 (3) , 167-170
Open AccessKnochen‑, Gelenk- und periprothetische Infektionen – eine interdisziplinäre Herausforderung
Zusammenfassung: Knochen- und Gelenkinfektionen umfassen ein breites Spektrum an Entitäten, insbesondere die Inzidenz von periprothetischen Infektionen, diabetischen Fußinfektionen und Spondylodiszitiden ist weiter zunehmend. Das Management ist komplex und ein interdisziplinäres Team aus v. a. Chirurgen, Infektiologen und Mikrobiologen ist zur Therapieplanung dringend zu involvieren. Die Evidenz zu den Behandlungsmöglichkeiten ist eher niedrig, aber in den letzten Jahren wurden einige Landmarkstudien veröffentlicht. Für die native Spondylodiszitis konnte eine Nichtunterlegenheit für eine 6‑ vs. 12-wöchige Antibiotikatherapie gezeigt werden, bei den periprothetischen Infektionen konnte die Nichtunterlegenheit für die 6‑wöchige Therapie dagegen nicht bestätigt werden. Eine frühe Oralisierung (innerhalb von 7 Tagen) bei verschiedenen Knocheninfektionen war nicht unterlegen, eine intravenöse Mindesttherapiedauer wird nicht mehr empfohlen.
- Open Access
- 12 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (16) , 4721
In Which Patients Do the 2023 Duke-ISCVID Criteria for Infective Endocarditis Increase the Diagnosis of “Definite Endocarditis”?—A Preliminary Analysis in the Prospectively Evaluated DERIVE Cohort
Background/Objectives: Recently, an update of the Duke criteria for the diagnosis of infectious endocarditis has been published: the 2023 Duke-ISCVID criteria. To gain an insight into which proportion of patients are affected by the new criteria, and which criteria might be the most relevant for the expected increase in sensitivity, we analysed data from a registry of cardiovascular infections. Methods: The 2023 Duke-ISCVID criteria were applied to patients who were diagnosed with and treated for endocarditis after having been classified as “possible” endocarditis according to the 2015 ESC Modified Duke criteria. In patients thus newly classified as “definite endocarditis”, diagnostic factors leading to this reclassification were described. Results: Of 397 patients, 48 (12%) did not fulfil the definition “definite infectious endocarditis” according to the 2015 ESC Modified Duke criteria. Of these, six (13%) fulfilled the definition when the 2023 Duke-ISCVID criteria were applied. A main factor triggering this reclassification was the consideration of microorganisms identified using valve PCR. Conclusions: As expected, the sensitivity of the new 2023 Duke-ISCVID criteria is increased in this cohort, mainly through the incorporation of new diagnostic methods in the criteria. Further studies are required to assess the effect on specificity in detail.
- 12 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (16) , 4721
Open AccessIn Which Patients Do the 2023 Duke-ISCVID Criteria for Infective Endocarditis Increase the Diagnosis of “Definite Endocarditis”?—A Preliminary Analysis in the Prospectively Evaluated DERIVE Cohort
Background/Objectives: Recently, an update of the Duke criteria for the diagnosis of infectious endocarditis has been published: the 2023 Duke-ISCVID criteria. To gain an insight into which proportion of patients are affected by the new criteria, and which criteria might be the most relevant for the expected increase in sensitivity, we analysed data from a registry of cardiovascular infections. Methods: The 2023 Duke-ISCVID criteria were applied to patients who were diagnosed with and treated for endocarditis after having been classified as “possible” endocarditis according to the 2015 ESC Modified Duke criteria. In patients thus newly classified as “definite endocarditis”, diagnostic factors leading to this reclassification were described. Results: Of 397 patients, 48 (12%) did not fulfil the definition “definite infectious endocarditis” according to the 2015 ESC Modified Duke criteria. Of these, six (13%) fulfilled the definition when the 2023 Duke-ISCVID criteria were applied. A main factor triggering this reclassification was the consideration of microorganisms identified using valve PCR. Conclusions: As expected, the sensitivity of the new 2023 Duke-ISCVID criteria is increased in this cohort, mainly through the incorporation of new diagnostic methods in the criteria. Further studies are required to assess the effect on specificity in detail.
- Open Access
- 13 March 2024
- Published by Springer Nature in Infection
- Vol. 52 (4) , 1407-1414
Outpatient parenteral antimicrobial therapy (OPAT) in Germany: insights and clinical outcomes from the K-APAT cohort study
Purpose: Outpatient parenteral antimicrobial therapy (OPAT) offers several key advantages, including enhanced patient quality of life, reduced healthcare costs, and a potential reduction of nosocomial infections. It is acknowledged for its safety and effectiveness. This study provides the first systematic clinical data for Germany, where OPAT has not yet been widely adopted. The aim is to establish a foundational reference point for further research and integration of OPAT into the German healthcare system. Methods: This prospective observational study descriptively analyses data obtained from a cohort of patients receiving OPAT. Both in- and outpatients from all medical specialties could be recruited. Patients administered the anti-infective medications themselves at home using elastomeric pumps. Results: 77 patients received OPAT, with a median duration of 15 days and saving 1782 inpatient days. The most frequently treated entities were orthopaedic infections (n = 20, 26%), S. aureus bloodstream infection (n = 16, 21%) and infectious endocarditis (n = 11, 14%). The most frequently applied drugs were flucloxacillin (n = 18, 23%), penicillin G (n = 13, 17%) and ceftriaxone (n = 10; 13%). Only 5% of patients (n = 4) reported to have missed more than one outpatient dose (max. 3 per patient). Only one catheter-related adverse event required medical intervention, and there were no catheter-related infections. Conclusion: The study demonstrates that OPAT can be safely conducted in Germany. In preparation for its broader implementation, crucial next steps include creating medical guidelines, fostering interdisciplinary and inter-sectoral communication, as well as creating financial and structural regulations that facilitate and encourage the adoption of OPAT. Trial registration number: NCT04002453.
- 13 March 2024
- Published by Springer Nature in Infection
- Vol. 52 (4) , 1407-1414
Open AccessOutpatient parenteral antimicrobial therapy (OPAT) in Germany: insights and clinical outcomes from the K-APAT cohort study
Purpose: Outpatient parenteral antimicrobial therapy (OPAT) offers several key advantages, including enhanced patient quality of life, reduced healthcare costs, and a potential reduction of nosocomial infections. It is acknowledged for its safety and effectiveness. This study provides the first systematic clinical data for Germany, where OPAT has not yet been widely adopted. The aim is to establish a foundational reference point for further research and integration of OPAT into the German healthcare system. Methods: This prospective observational study descriptively analyses data obtained from a cohort of patients receiving OPAT. Both in- and outpatients from all medical specialties could be recruited. Patients administered the anti-infective medications themselves at home using elastomeric pumps. Results: 77 patients received OPAT, with a median duration of 15 days and saving 1782 inpatient days. The most frequently treated entities were orthopaedic infections (n = 20, 26%), S. aureus bloodstream infection (n = 16, 21%) and infectious endocarditis (n = 11, 14%). The most frequently applied drugs were flucloxacillin (n = 18, 23%), penicillin G (n = 13, 17%) and ceftriaxone (n = 10; 13%). Only 5% of patients (n = 4) reported to have missed more than one outpatient dose (max. 3 per patient). Only one catheter-related adverse event required medical intervention, and there were no catheter-related infections. Conclusion: The study demonstrates that OPAT can be safely conducted in Germany. In preparation for its broader implementation, crucial next steps include creating medical guidelines, fostering interdisciplinary and inter-sectoral communication, as well as creating financial and structural regulations that facilitate and encourage the adoption of OPAT. Trial registration number: NCT04002453.
- Open Access
- 31 January 2024
- Published by Springer Nature in Infection
- Vol. 52 (3) , 1159-1163
Flucloxacillin and cefazolin for treatment of Staphylococcus aureus bloodstream infection
Purpose: Antistaphylococcal penicillins and cefazolin have been used as first line therapy in Methicillin-susceptible Staphylococcus aureus bloodstream infection. While efficacy of both regimens seems to be similar, the compounds may differ with regard to tolerability. This study aims to describe the clinical use of cefazolin and flucloxacillin, focussing on discontinuation or change of anti-infective agent due to adverse events. Methods: This observational prospective study was conducted at two German tertiary care centres with an internal recommendation of flucloxacillin for MSSA-BSI in one, and of cefazolin in the other centre. Adverse events were registered weekly under treatment and at a 90-day follow-up. Descriptive analysis was complemented by a propensity score analysis comparing adverse events (stratified rank-based test applied to the sum of Common Terminology Criteria for adverse events ratings per patient). Results: Of 71 patients included, therapy was initiated with flucloxacillin in 56 (79%), and with cefazolin in 15 (21%). The propensity score analysis indicates a statistically significant difference concerning the severity of adverse events between the treatment groups in favour of cefazolin (p = 0.019). Adverse events led to discontinuation of flucloxacillin in 7 individuals (13% of all patients receiving flucloxacillin). Clinical outcome was not different among treatment groups. Conclusion: Using cefazolin rather than flucloxacillin as a first line agent for treatment of MSSA-BSI is supported by these clinical data.
- 31 January 2024
- Published by Springer Nature in Infection
- Vol. 52 (3) , 1159-1163
Open AccessFlucloxacillin and cefazolin for treatment of Staphylococcus aureus bloodstream infection
Purpose: Antistaphylococcal penicillins and cefazolin have been used as first line therapy in Methicillin-susceptible Staphylococcus aureus bloodstream infection. While efficacy of both regimens seems to be similar, the compounds may differ with regard to tolerability. This study aims to describe the clinical use of cefazolin and flucloxacillin, focussing on discontinuation or change of anti-infective agent due to adverse events. Methods: This observational prospective study was conducted at two German tertiary care centres with an internal recommendation of flucloxacillin for MSSA-BSI in one, and of cefazolin in the other centre. Adverse events were registered weekly under treatment and at a 90-day follow-up. Descriptive analysis was complemented by a propensity score analysis comparing adverse events (stratified rank-based test applied to the sum of Common Terminology Criteria for adverse events ratings per patient). Results: Of 71 patients included, therapy was initiated with flucloxacillin in 56 (79%), and with cefazolin in 15 (21%). The propensity score analysis indicates a statistically significant difference concerning the severity of adverse events between the treatment groups in favour of cefazolin (p = 0.019). Adverse events led to discontinuation of flucloxacillin in 7 individuals (13% of all patients receiving flucloxacillin). Clinical outcome was not different among treatment groups. Conclusion: Using cefazolin rather than flucloxacillin as a first line agent for treatment of MSSA-BSI is supported by these clinical data.
- Open Access
- 30 January 2024
- Published by Springer Nature in Die Innere Medizin
- Vol. 65 (3) , 228
Erratum zu: Präzisionsmedizin in der Infektiologie
- 30 January 2024
- Published by Springer Nature in Die Innere Medizin
- Vol. 65 (3) , 228
Open AccessErratum zu: Präzisionsmedizin in der Infektiologie